Journal
CANCER LETTERS
Volume 337, Issue 1, Pages 77-89Publisher
ELSEVIER IRELAND LTD
DOI: 10.1016/j.canlet.2013.05.017
Keywords
qHTS; SUM149; SUM190; Lapatinib; XIAP; Redox adaptation
Categories
Funding
- NIH [CA137844, T32CA009111]
- American Cancer Society [RSG-08-290-01-CCE]
- Duke Comprehensive Cancer Institute
- Golden LEAF Foundation
- BIOIMPACT Initiative of the State of North Carolina
Ask authors/readers for more resources
Although there is no standard treatment protocol for inflammatory breast cancer (IBC), multi-modality treatment has improved survival. In this study we profiled the NCI approved oncology drug set in a qHTS format to identify those that are efficacious in basal type and ErbB2 overexpressing IBC models. Further, we characterized the sensitivity of an acquired therapeutic resistance model to the oncology drugs. We observed that lapatinib-induced acquired resistance in SUM149 cells led to cross-resistance to other targeted- and chemotherapeutic drugs. Removal of the primary drug to which the model was developed led to re-sensitization to multiple drugs to a degree comparable to the parental cell line; this coincided with the cells regaining the ability to accumulate ROS and reduced expression of anti-apoptotic factors and the antioxidant SOD2. We suggest that our findings provide a unique IBC model system for gaining an understanding of acquired therapeutic resistance and the effect of redox adaptation on anti-cancer drug efficacy. (C) 2013 Elsevier Ireland Ltd. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available